Two of the largest and most influential doctor associations in the country -- the American Academy of Allergy Asthma & Immunology and the American College of Allergy, Asthma & Immunology -- issued a joint statement, saying that the FDA's probe into the link between the asthma drug Singulair and its links to suicide and suicidal behavior "is based entirely on case reports and there is no indication that such effects apply to other leukotriene-modifying medications."
Remember, the FDA said it is reviewing the asthma medication after receiving reports of mood and behavior changes, suicidal thinking and suicide in patients who took Singulair.
"No causal relationship has been established," the FDA said last week.
You can read the entire joint statement here.
The organizations finish their statement with this recommendation for patients: "Based on the information currently available, patients taking Singulair should continue to take the medication as prescribed provided: 1) the patient and physician feel the medication is effective; and 2) the patient does not experience any suicidal behavior or thoughts."
We asked you to weigh in on the debate and tell us if you were thinking of stopping Singulair.
Find the results of the Singulair Poll Here.
Singulair and Asthma: Getting Scared Smart
The FDA and Singulair -- Can we trust the agency to keep us safe?
Singulair Drug Information Page